Search results
Author(s):
Stefan Stortecky
Added:
2 years ago
AHA 23 — We are joined onsite by Prof Stefan Stortecky (Bern University Hospital, Bern, SE) to discuss the findings of the single centre SPECIAL trial that investigated ultrasound-assisted catheter-directed thrombolysis as compared to surgical pulmonary embolectomy for intermediate high or high risk pulmonary embolism.Questions1. What is the reasoning behind this study?2. What is the patient…
View more
Pulmonary Embolism Management
Author(s):
Andrew SP Sharp
,
Gilles Lemesle
,
Start date:
Oct 07, 2025
Broadcast
Author(s):
Akshyaya Pradhan
,
Richa Tyagi
,
Prachi Sharma
,
et al
Added:
1 year ago
Author(s):
Nicolas M Van Mieghem
,
Joost Daemen
Added:
2 years ago
What should you keep an eye out for at this year's AHA Scientific Sessions?Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, NL) return with their 'View from the Thoraxcenter' preview to highlight late-breaking and featured science trials being presented at this year's AHA Scientific Sessions. Join this dynamic discussion on some of the most anticipated data releases.The…
View more
Author(s):
Dr Wissam A Jaber
Added:
1 year ago
TCT Conference 24 - PEERLESS II shows benefit of large-bore mechanical thrombectomy compared to catheter-directed thrombolysis for intermediate-risk pulmonary embolism (PE) patients.Dr Wissam A Jaber (Emory University Hospital Midtown, US) joins us onsite at TCT Conference to discuss the findings from PEERLESS (NCT06055920; Inari Medical).PEERLESS is a prospective, multicenter, randomized…
View more
Author(s):
Rick Veasey
Added:
1 year ago
ESC Congress 24 — SHAM-PVI study finds pulmonary vein isolation effective in reducing atrial fibrillation (AF) episodes, improving quality of life.We are joined onsite by Dr Rick Veasey (Eastbourne District General Hospital, Eastbourne, UK) to discuss the findings from a SHAM-PVI, a randomized sham-controlled study of pulmonary vein isolation in symptomatic atrial fibrillation (NCT04272762; East…
View more
Author(s):
Kazuya Hosokawa
,
Abe Kotaro
Added:
2 years ago
AHA 2023 — Dr Kazuya Hosokawa and Dr Abe Kotaro (Kyushu University Hospital, JP) join us to share the findings of the KABUKI trial (NCT04730037). The aim of KABUKI (Daiichi Sankyo) is to assess whether edoxaban, a direct factor Xa inhibitor, is noninferior to warfarin in preventing worsening of chronic thromboembolic pulmonary hypertension (CTEPH).This investigator-initiated, multicenter, phase 3…
View more
Zoltán Ruzsa
Job title: Head of Invasive Cardiology (Invasve Cardiology)
Author
Sylwia Sławek-Szmyt
Job title: Interventional Cardiologist
Author
Author(s):
Anastasia Shchendrygina
,
Ilya Giverts
,
Mariya Tokmakova
,
et al
Added:
1 year ago